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Background: Around 10 per cent of catecholamine-secreting tumours can be found outside the adrenal medulla
(paraganglioma). We report a case of a functional sporadic paraganglioma that was localized lateral to the prostate
without causing lower urinary tract symptoms.
Case presentation: A 76-year old male with an extensive history of cardiovascular disease suffered from hypertension
and an unexplained hypochromic microcytic anaemia for years before the coincidental discovery of a 2.5 × 3.5 cm
periprostatic mass upon abdominal contrast-enhanced CT scanning. Transrectal biopsies revealed a paraganglioma.
The urinary levels of the catecholamine metabolites were found increased. The paraganglioma showed uptake of
iodine-123-metaiodobenzylguanidine by SPECT scanning, indicating a solitary lesion. Successful preperitoneal
endoscopic resection of the tumour was performed, which resulted in a decrease in blood pressure and a
normalization of the urinary catecholamine metabolites. None of the to date known genetic mutations that have been
shown to relate to the existence of paragangliomas were identified in the current case.
Conclusion: An intra- or periprostatic localization of a paraganglioma is very rare. We reviewed the literature and found
6 other cases. Three of the described cases presented with lower urinary tract symptoms. In these three patients, the
tumour had a size of 4 cm or larger and in 67 per cent of these cases the paragangliomas were situated within the
prostate. The periprostatic region might be considered as a possible location for paragangliomas, especially in the
presence of lower urinary tract symptoms even though they were absent in the current case.
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urinary tract symptomsBackground
Pheochromocytomas and paragangliomas are charac-
terized by a large diversity of clinical features and as a
result can remain unrecognized for years. General fea-
tures of these catecholamine-producing tumours, which
originate from the sympathetic nervous system, are re-
lated to the response to stress, i.e. paroxysms of hyper-
tension, paleness, headache and sweating attacks [1].
Pheochromocytomas are rare with an incidence of 8
new cases per 100.000 persons per year peaking around
the fourth decade of life. The prevalence of pheo-
chromocytoma in patients with hypertension, its major* Correspondence: j.kers@amc.uva.nl
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reproduction in any medium, provided the orpresenting symptom, is around 0.1%. Pheochromocyto-
mas are often found as an incidentaloma of the adrenal
medulla upon medical imaging, but in around 10% of
cases, they originate from autonomic nervous cells
outside the adrenal glands in the neck, the thorax or
the abdomen and pelvis (extra-adrenal catecholamine-
secreting tunours are referred to as paragangliomas).
In this article, we describe a rare case of a 76-year old
male who presented with a sporadic functional paragan-
glioma that was situated at a very unusual localization,
namely lateral to the prostate. A review of the available
literature on this specific topic is provided.
Case presentation
A 76-year old man was referred to the outpatient clinic
of the internal medicine department of our hospital. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
AB
C
Figure 1 (See legend on next page.)
Kers et al. BMC Endocrine Disorders 2013, 13:55 Page 2 of 7
http://www.biomedcentral.com/1472-6823/13/55
(See figure on previous page.)
Figure 1 Blood pressure and heart rate registrations pre-, peri- and post-surgery. Fifteen-hour registration, starting at 15 h in the afternoon
(T = 0) until 6 h in the morning (T = 15), shows a sustained hypertension (A). Blood pressure and heart rate monitoring during the preperitoneal
endoscopic resection of the paraganglioma shows an increase in sympathetic activity at start of intubation that is further augmented when the
tumour is manipulated (B). When the tumour was removed, sympathetic activity lowered. The heart rate remained constant throughout the
procedure. Postoperative monitoring indicates that there is a remainder of systolic blood pressure variability, which is common after removal of
paraganglioma (C).
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been present since 2010. The patient had an extensive
history of cardiovascular disease. In 1985 he suffered
from an acute myocardial infarction for which he under-
went percutaneous transluminal coronary angioplasty
of the circumflex branch of the left coronary artery.
He was treated for two thromboembolic events: a deep
venous thrombosis of his right leg in 2008 and pulmo-
nary embolism in 2009. Over the past years he de-
veloped a therapy-resistant hypertension, which was,
which was presumed initially due to white coat phe-
nomenon. Figure 1A illustrates the 15-hours continuous
blood pressure registration at that time, which did not
confirm this hypothesis, showing a sustained hypertension
pattern. In 2010 he was diagnosed with hypertensive car-
diomyopathy that resulted in decompensated heart failure
two years later. Furthermore, the patient had a history of
type 2 diabetes mellitus, hypercholesterolemia, psoriasis
and macular degeneration. His anti-hypertensive medi-
cation consisted of amlodipine/valsartan/hydrochlorothia-
zide 1 dd 5/160/12.5 mg, furosemide 1 dd 40 mg and
nebivolol 1 dd 5 mg. Furthermore he was using atorvasta-
tine 1 dd 40 mg, carbasalate calcium 1 dd 100 mg, metfor-
mine 2 dd 500 mg, paroxetine 1 dd 10 mg, oxazepam 1 dd
10 mg, pantoprazole 1 dd 40 mg, ferrous fumarate and
rizatriptan 10 mg whenever needed.
Upon arrival at the medical outpatient clinic, he com-
plained of dyspnea on exertion that had been stable since
he was diagnosed with decompensated heart failure. He
also complained of paroxysmal headaches without aber-
rant palpitations, increased transpiration or paleness. In
the context of the persisting anaemia, which was the initial
reason for referral, he had not noticed a change in his
defecation pattern over the past years and especially no
melaena or bloody stool had been present. Further labora-
tory investigation showed a low mean corpuscular volume
and hemoglobin concentration with a low serum iron and
ferritin, but a high iron-binding capacity, indicative of
hypochromic microcytic anaemia in the context of an iron
deficiency (Table 1). The absolute erythrocyte count was
within the normal range. In 2010, no cause for his
anaemia was found on gastroduodenoscopic and colono-
scopic evaluation. A screening CT-scan of the thorax and
abdomen with intravenous and rectal contrast was per-
formed to screen for any possible primary malignancy.The abdominal CT-scan showed a round and sharply de-
marcated tumour of 1.7 by 2.5 cm in close proximity to
the bladder wall on the right side of the patient’s prostate
(Figure 2A and B). The average post-contrast radiodensity
of the tumour measured 90 Hounsfield units, which did
not have additional value for the differential diagnosis due
to the contrast. No local lymphadenopathy was detected.
The findings of the CT-scan were confirmed by digital
rectal examination, where an asymmetrically and irregu-
larly enlarged tumour with a hard node was felt and the
patient was referred to the urologist for further evaluation
under the suspicion of a prostate tumour.
When he presented at the urology department, his
serum total prostate-specific antigen concentration was
2.5 μg/L (reference value for the age of 70 – 80 < 6.5 μg/L).
At that time, the patient had no lower urinary tract symp-
toms and his headache had not worsened during mictu-
rition. Cystoscopy revealed an impression of the right
bladder wall with no mucosal pathology. Three transrectal
ultrasonography-guided biopsies of the lesion where
obtained and histological analysis of the material with
hematoxylin staining showed partly tube-forming tumo-
rous epithelial cells with intensely stained nuclei that dif-
fered in size (Figure 2D). Immunohistochemical analysis of
the tissue showed hardly any proliferating cells by Ki-67
staining, but intense staining for chromogranin A
(Figure 2D, inlet), synaptofysin and neural cell adhesion
molecule (NCAM), consistent with the phenotype of a
paraganglioma. Immunohistochemistry for markers of
prostatic tissue to rule out prostatic cancer, i.e. prostate-
specific antigen (PSA) and prostate-specific acid phos-
phatase (PSAP), were both negative. Further laboratory
investigation to determine catecholamine excess was
performed by 24-hours urine analysis on their metabo-
lites. In two separate 24-hours urine samples, the con-
centrations of the fractionated metanephrines were
found increased (Table 2), which could not be explained
by a concomitant psychiatric illness the use of sym-
pathomimetic drugs or medicaments. Monoamine oxi-
dase inhibitors were not used. SPECT-scanning with
iodine-123-metaiodobenzylguanidine (123I-MIBG), a mo-
lecule similar to norepinephrine and taken up in adrener-
gic tissue showed pathological uptake solely within the
paraganglioma (Figure 2C). By evaluation of the patient’s
serum, hyperparathyroidism was found that could be,
Table 1 Chemical, haematological and endocrinological
work-up on initial presentation at the medical
outpatient clinic
Serum chemistry Value Reference
Sodium (mmol/L) 135 135 – 145
Potassium (mmol/L) 4.5 3.5 – 4.5
Calcium (mmol/L) 2.66 (corr. 2.68) ⬆ 2.10 – 2.55
Phosphate (mmol/L) 0.8 ⬇ 0.9 – 1.5
Magnesium (mmol/L) 0.9 0.7 – 1.0
Albumin (g/L) 39 35 – 55
Creatinine (μmol/L) 88 80 – 125
eGFR CKD-EPI (mL/min/1.73 m2) 73 >60
Morning glucose 5.9 4.0 – 6.4
HbA1c (mmol/mol) 41 <53
Iron (μmol/L) 5 ⬇ 14 - 35
Total iron-binding capacity (μmol/L) 75.3 ⬆ 27 – 54
Ferritin (μg/L) 16 ⬇ 25 – 250
Folic acid (nmol/L) 55.7 ⬆ 5 – 23
Vitamin B12 (pmol/L) 364 130 – 700
Alkaline aminotransferase (U/L) 18 <50
Aspartate aminotransferase (U/L) 12 <45
Alkaline phosphatase (U/L) 89 <125
Gamma-glutamyltransferase (U/L) 67 ⬆ <45
Total bilirubin (μmol/L) 7 <17
C-reactive protein (mg/L) 4.6 <10
25-hydroxy vitamin D (nmol/L) 19 ⬇ 20 – 100
Hematology
Hemoglobin (mmol/L) 7.4 ⬇ 8.5 – 11.0
Mean corpuscular volume (fL) 79.9 ⬇ 82 – 98
Mean corpuscular hemoglobin (fmol) 1.6 ⬇ 1.7 – 2.1
Erythrocyte count (1012/L) 4.73 4.3 – 6.0
Erythrocyte sediment rate (mm/uur) 53 ⬆ <20
Thrombocytes count (109/L) 381 150 – 400
Leukocyte count (109/L) 7.6 4.0 – 10.0
Endocrinology
Thyroid-stimulating hormone (mU/L) 2.3 0.5 – 3.9
Free thyroxine (pmol/L) 10.5 9 – 24
Parathyroid hormone (pmol/L) 9.4 ⬆ 2 – 7
Calcitonin (pmol/L) 5.1 <25
Prostate-specific hormone (μg/L) 2.5 <6.5
Urine (24-hours collection)
Calcium (mmol/L) 4.3 3.5 – 8.0
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multiple endocrine neoplasia 2a syndrome (MEN2a).
Additional serum analysis showed a corrected calciumconcentration of 2.68 mmol/L and moderate hypovita-
minosis D (Table 1). A sestamibi parathyroid scintig-
raphy was performed with 99mTc-MIBI and substraction
with 123I that showed no washout suspected for para-
thyroid adenoma or hyperplasia. Under the provisional
diagnosis of secondary hyperparathyroidism, vitamin D
was supplemented, which resulted in a normalization of the
corrected serum calcium concentration to 2.45 mmol/L.
With a serum calcitonin concentration of 7.4 pmol/L
(reference <24 pmol/L) and a carcinoembryonic antigen
(CEA) concentration of 3.3 μg/L (reference in non-
smokers < 5.0 μg/L), medullary thyroid cancer became less
likely. Since extra-adrenal pheochromocytomas have been
shown to be more prevalent in patients with a hereditary
paraganglioma syndrome, genetic screening was indicated.
Various schemes for genetic screening based on risk fac-
tors for mutations have been proposed, which include
screening for RET, SDHB, SDHD and VHL in case of
abdominal paragangliomas [2,3]. Erroneously, all to date
known genes that are related to pheochromocytomas and
paragangliomas were sequenced, including multiplex
ligation-dependent probe amplification (MLPA) to detect
larger deletions (RET, MAX, SDHA, SDHAF2, SDHB,
SDHC, SDHD, TMEM127 and VHL; MRC-Holland kit
P226-B2), but none showed pathogenic mutations in their
coding sequence or splice sites.
The patiënt was scheduled for preperitoneal endoscopic
resection of the paraganglioma and Figure 2E shows a
snapshot of the peri-prostatically localized tumour via the
endoscopy camera. Prior to surgery the patient’s blood
pressure was lowered according to the scheme proposed
by Pacak [4]. First, 4 weeks prior to surgery nebivolol was
halted due to the chance of paradoxical hypertensive cri-
ses with beta blockade. Alpha blockade with doxazosine
was initiated and increased up till 1 dd 32 mg. Secondly,
beta-blockade with metoprolol retard 1 dd 50 mg and sub-
sequently nifedipine retard 1 dd 30 mg were added to the
regimen, which resulted in a pre-operative blood pressure
of 140/80 mmHg. Pre-operative resuscitation with NaCl
0.9% was performed in order to reduce intravascular dehy-
dration. Blood pressure was closely monitored pre-, per-
and post-operation. At the start of intubation by the
anesthesiologist, blood pressure started to rise (Figure 1B).
Preperitoneal carbondioxide inflation caused the blood
pressure to increase by another 30% systolically and dia-
stolically and manipulation of the paraganglioma resulted
in a systolic and diastolic blood pressure above 230 and
100 mmHg, respectively. After removal of the para-
ganglioma systolic and diastolic blood pressure dropped
(Figure 1B). During 2 hours post-operative monitoring,
blood pressure remained between 120 and 160 mmHg
systolically and 60 and 90 mmHg diastolically (Figure 1C).
Two days after surgery, his blood pressure could be ad-
equately regulated by metoprolol only. One month after
Figure 2 Abdominal computed tomography, 123I-MIBG scintigraphy, pathology and preperitoneal endoscopic resection of the
pheochromocytoma. Axial (A) and coronal view (B) on abdominal computed tomography with intravenous and rectal contrast shows a
round-shaped, sharply demarcated tumour of 1.7 by 2.5 cm possibly attached to the bladder wall just lateral to the prostate. No local (or distant)
lymphadenopathy was observed. Arrowheads in red indicate the tumour. The iodine-123-metaiodobenzylguanidine (123I-MIBG) SPECT-scan
shows high uptake of 123I in the periprostatic tumour without suspicion of catecholamine-producing tumours located elsewhere in the body
(C). Furthermore, aspecific uptake can be observed in the liver and also the bladder through renal clearance of the (coupled) isotope. “R” indicates the
right side of the patient and “L” indicates the liver. The red arrow indicates the tumour uptake of 123I-MIBG. Hematoxylin staining of the transrectal
biopsies of the tumour showed epithelial cells with dark nuclei that differed in size with local tube formation (D). In the cytoplasm of the epithelial
cells, a granular pattern was observed. Immunohistochemistry of the tissue shows a positive staining for chromogranin A, CD56 and synaptofysin.
Staining for PSA and PSAP, which might be indicative of prostatic tissue, were negative. The inlet illustrates the chromogranin A immunostaining on
the tumour tissue. Snapshot of the camera during preperitoneal endoscopic resection of the paraganglioma shows the close proximity to the prostate
(E). The peri-prostatic fat is indicated in light-blue by “PPF” and the tumour by “T”. Gross macroscopy of the 3.5 by 2.5 by 2 cm partly encapsulated
tumour that was resected via preperitoneal endoscopic surgery (F).
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treatment was 160/100 mmHg with a heart rate of 90
beats per minute and hydrochlorothiazide/valsartan 1 dd
12.5/80 mg was initiated, which resulted in blood pressure
of 150/90 mmHg. Pathologic examination of the excised
tumour, which had a diameter of 2.5 - 3.5 cm on gross
macroscopy, confirmed the diagnosis of paragangliomaTable 2 Urinalysis of metabolites of the catecholamines
Pre-operative
First urinalysis Second urinalys
Metanephrine (μmol/24 h) 1.1 2.4
Normetanephrine (μmol/24 h) 7.1 16.8(Figure 2F). One year after resection of the paraganglioma,
the patient was readmitted to the medical ward again with
a microcytic anaemia and reticulocytosis. Under the suspi-
cion of gastrointestinal blood loss, gastroduodenoscopy
and colonoscopy plus videocapsule endoscopy have been
planned. To date, the microcytic anaemia is not believed
to be associated with the paraganglioma.Post-operative
is 2 weeks urinalysis 5 months urinalysis Reference
0.9 1.2 <2.0
5.7 4.9 <5.0
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Here we documented the case of a 76-year old male with
symptoms of sustained therapy-resistant hypertension,
unexplained microcytic anaemia and a catecholamine-
producing tumour near the prostate that had remained
unrecognized for years. The paraganglioma was disco-
vered incidentally on a screening abdominal CT scanning
made during the work-up for his unexplained and pre-
sumably unrelated anaemia.
To the best of our knowledge, this is the seventh case in
history reporting a paraganglioma that is localized in or in
close proximity to the prostate [5-10]. Compared to the
other described cases, the current patient is relatively old
at time of diagnosis and the tumour size was the smallest
in the range (Table 3). None of the cases mentioned
(microcytic) anaemia at time of diagnosis. Remarkably,
three of the described cases presented with symptoms re-
lated to micturition; in two of these cases the paragang-
liomas were situated within the prostate and all cases that
had complaints related to micturition had a tumour size
of 4 cm or larger (Table 3). Of the 7 cases, 5 patients
(71%) originated from Europe.
Besides the classical triad of paroxysmal palpitations,
headache and sweating, which are direct signs of sym-
pathetic activation [1], pheochromocytomas and para-
gangliomas may present with a variety of cardiovascular
manifestations related to this classical triad as well [12,13].
Interestingly, our patient did not present with any of
the classical symptoms related to catecholamine excess
and is primary symptom was a sustained therapy resistant
hypertension. In a report by Zelinka and colleagues,
19% of patients that later presented with a functionalTable 3 Comparison of cases of (peri)prostatically localized p
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N.D. = not described.pheochromocytoma had prior cardiovascular complica-
tions that included arrhythmias, tako-tsubo-like cardiomy-
opathy and even myocardial infarction and stroke [13]. In
the case presented in the current manuscript, the patient
had been diagnosed with hypertensive cardiomyopathy
two years before the diagnosis of paraganglioma, which is
in line with the report by Zelinka and colleagues.
Extra-adrenal localization of catecholamine-secreting tu-
mours is more often in the context of a genetic syndrome
and it is therefore recommended to screen these patients
for underlying genetic mutations [2]. The current report is
the first in the literature that describes screening in a case
of a (peri)prostatically localized paraganglioma [1,14]. By
mistake, the full spectrum of to date known germline mu-
tations was analysed, which is not cost effective. In the
current patient, the internally validated scheme by Erlic
et al. advices to start with screening for SDHB followed by
VHL, SDHD and RET in case of a single paraganglioma,
which is not located in the head and neck region [2]. We
advice to follow risk factor guided mutation screening,
since these schemes were shown to have a high c-statistic
for detection of germline mutations and costs can be re-
duced up till 40% as compared to a screening in prede-
fined order (SDHB >VHL > RET > SDHD) in each patient
presenting with a catecholamine-secreting tumour.
In conclusion, we describe the case of a functional
periprostatic pheochromocytoma, which is an unusual
extra-adrenal site of presentation for this type of neopla-
sia. The tumour was recognized on a contrast-enhanced
CT scan performed in the work up for unexplained and
presumably unrelated microcytic anaemia. Although
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in the presence of lower urinary tract symptoms even
though they were absent in the current case.
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